Mentions in press and media 6
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Oct 2, 2025 | Life sciences companies make positive progress | At Synendos Therapeutics, topline results of the phase 1 clinical trial for its lead asset, SYT-510, a first-in-class inhibitor that modulates a newly identified drug target in the Endocannabinoid System that helps restore healthy brain fu... |
| Mar 19, 2025 | Biotech updates: A first dosing and a setback | LimmaTech Biologics AG, a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, launched the Phase 1 clinical trial (NCT06719219) in the U.S. after receiving a Fast Track designation from the U.... |
| May 1, 2024 | Triumphs and a setback in the biotech sector | The successful advancement of CDR-Life Inc.’s Phase 1 study with BI 771716, its therapeutic candidate in partnership with Boehringer Ingelheim (BI) for the treatment of geographic atrophy (GA), has triggered a milestone payment to the star... |
| Mar 20, 2024 | FDA approvals and encouraging results for innovative therapies | Idorsia announced today that the US Food and Drug Administration (FDA) has approved TRYVIO (aprocitentan) for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adult patients who are... |
| Jan 30, 2023 | Piqur assets sold to Swiss Rockets affiliate |
Reviews 0
FAQ about Torqur.com
What has the press written about Torqur.com?
Parsers VC has collected 6 articles mentioning Torqur.com, among them “Life sciences companies make positive progress” (Oct 2, 2025) and “Biotech updates: A first dosing and a setback” (Mar 19, 2025).
Is Torqur.com still active?
Yes, Torqur.com is active; its latest activity on Parsers VC dates from Sep 11, 2026.